Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 19/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836341 | 0.99 | CETP (0.58) | CETPKCNH2ESR1ESR2 | |
| SCHEMBL15088548 | 0.90 | CETP (0.58) | CETPKCNH2ESR1ESR2 | |
| SCHEMBL13204475 | 0.89 | CETP (0.57) | CETPKCNH2ESR1ESR2 | |
| Lithium Ion SCHEMBL3683380 | 0.88 | CETP (0.56) | CETPKCNH2ESR1ESR2 | |
| SCHEMBL2831505 | 0.87 | CETP (0.63) | CETPKCNH2 | |
| SCHEMBL13984543 | 0.87 | CETP (0.62) | CETPKCNH2 | |
| SCHEMBL3679844 | 0.85 | CETP (0.63) | CETP | |
| SCHEMBL2840010 | 0.84 | CETP (0.57) | CETPKCNH2 | |
| SCHEMBL3807420 | 0.84 | CETP (0.64) | CETP | |
| SCHEMBL3643413 | 0.83 | CETP (0.47) | CETPKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170058-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8445480-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2170058-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156715-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | CETP 1/4885KCNH2 2428/4885ESR1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.